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Stenosis in the Era of Transcatheter
Aortic Valve Replacement*
Anetta Undas, MD, PHD,yz Joanna Natorska, PHDyzA ortic stenosis (AS) increasingly afﬂicts ouraging population, affecting about 0.2% inindividuals 55 to 64 years of age and 2% to
3% in subjects older than 65 years of age. In up to
20% of patients with moderate-to-severe AS, mucous
nasopharyngeal and cutaneous bleedings are ob-
served, whereas gastrointestinal (GI) bleeding occurs
in 1% to 3% of the patients. GI bleeds in patients with
severe AS are usually associated with angiodyspla-
sia—multifocal submucosal vascular malformations
formed probably as a result of increasing wall tension
during colonic contractions, which is the second most
common cause of lower GI bleeding in patients >60
years of age (the so-called Heyde syndrome [HS]) (1).
Compelling evidence for the pathophysiological link
between AS and bleeding from angiodysplasia stems
from the resolution of GI bleeding observed during
the ﬁrst 7 days after surgical aortic valve replacement
(AVR) (2), although the abnormal vessels remained
visible on colonoscopy. A major mechanism underly-
ing increased bleeding risk in AS represents acquired
type 2A von Willebrand syndrome that is character-
ized by a quantitative deﬁciency of high molecular
weight multimers (HMWM) of von Willebrand factor
(vWF) (3). Other mechanisms not associated with
type 2A von Willebrand syndrome could also been
involved in bleeding risk observed in severe AS (4).
vWF that is predominantly synthesized in endothelial
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paper to disclose.glycoprotein assembled from identicalw250kDa subunits
into disulﬁde-linked multimers up to >20,000 kDa. vWF
is essential for platelet-subendothelium adhesion and
platelet-to-platelet interactions under high shear stress
conditions, such as in angiodysplasia. The most effective
in platelet-mediated hemostasis are the vWF HMWM,
deﬁned usually as the presence of >10 dimers of vWF,
which represent w30% of the circulating molecules in
healthy individuals (5). In areas of high shear stress, the
conformational structure of the vWF can be altered,
leading to exposure of the bond between Tyr842 and
Met843, which is cleavage-sensitive to a speciﬁc metal-
loprotease (ADAMTS13 [a disintegrin-like and metal-
loprotease with thrombospondin type 1 motif 13]) (6). It
has been shown that 20% to 70% of AS patients have
a marked reduction in the percentage of vWF HMWM
(7,8), and this value correlates with the transvalvular
gradients (8). AVR decreases GI bleeding in 93% of pa-
tients with angiodysplasia, whereas GI surgery produces
a durable remission in as few as 5% of the patients (9).
In the transcutaneous aortic valve intervention
(TAVI) cohort, 9.2% of elderly patients unﬁt for AVR
had a history of GI bleeding or anemia, including 6%
with GI bleeding unrelated to angiodysplasia, 1.5%
with bleeding from undeﬁned origin, and 1.7% with
documented HS (10). HS was reported to increase the
periprocedural bleeding risk during TAVI, which is
an effective therapeutic option in the setting of GI
bleeding, with severe transfusion-dependent anemia
observed only for the patient in whom TAVI failed
(10). Benton et al. (11) also demonstrated cessation of
massive GI bleeding with post-procedural recovery of
vWF HMWM after TAVI.
The study by Spangenberg et al. (12) in this issue
of JACC: Cardiovascular Interventions performed
in 95 elderly patients with severe AS undergoing
transfemoral transcatheter aortic valve replacement
(TAVR) increases our knowledge of the impact of
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702this intervention on bleeding risk, in particular
bleeding associated with abnormal vWF multimers.
The authors conﬁrmed that a high proportion (42%)
of the AS patients had type 2A von Willebrand syn-
drome with a relatively high content of vWF HMWM
of about 16% that, as expected, was strongly correlated
with mean transvalvular gradients. Interestingly,
only 18% of the patients reported bleeding before
TAVR, including GI bleeding noted in 11% (12). In line
with previous ﬁndings (1,3,7), only a subset of AS pa-
tients with type 2A von Willebrand syndrome experi-
enced clinically overt bleeding, indicating that there
are other modulators of bleeding risk in this disease,
involving inherent and environmental individual he-
mostatic proﬁle. What, then, might reduce bleeding
risk in severe AS? Potential mechanisms that may
support hemostasis despite decreased vWF HMWMSEE PAGE 692and reduce bleeding risk in a subset of AS patients
involve enhanced thrombin generation and platelet
activation reﬂected by higher soluble CD40 ligand in
circulating blood (8), formation of procoagulant mi-
croparticles (13), and impaired ﬁbrinolysis in part
mediated by increased release of plasminogen acti-
vator inhibitor-1 (14). Higher local thrombin genera-
tion is likely to potentiate platelet activation and
aggregation, which might improve local hemostasis
also at high shear stress in the bleeding-prone lesions.
It would be of interest to look at thrombin generation
and efﬁciency of ﬁbrin formation and degradation
before and after TAVR as the factors that might help
identify subjects deﬁcient in vWF HMWM who are
prone to GI bleeding.
Spangenberg et al. (12) provided additional evi-
dence that abnormal vWF multimer pattern related to
high shear stress improves in about 90% of the pa-
tients after TAVR, with a still lower HMWM content in
these subjects compared with the control group.
The remaining patients comprised individuals with
mild-to-moderate aortic regurgitation or paravalvular
leakage 2þ or more after TAVR, who displayed a
decrease in vWF HMWM within a week from the
procedure. Of note, a deﬁciency of vWF HMWM in the
TAVR population showed no association with the
risk of blood transfusions during the procedure andaccess site bleeding despite aspirin (100 mg/day)
with clopidogrel (loading dose of 600 mg followed
by 75 mg/day) plus intravenous unfractionated hep-
arin during the procedure. Of note, type 2A von Wil-
lebrand syndrome does not increase 1-year mortality
following TAVR (12). This indicates that a less inva-
sive TAVR is safer than AVR mainly due to elimina-
tion of the large chest wound and reduction in
HMWM vWF during cardiovascular bypass.
From a methodological point of view, it should be
highlighted that the ratio of vWF collagen-binding
activity (vWF:CB) to vWF antigen (vWF:Ag), a stan-
dard diagnostic test to assess to the functionality of
vWF, was not determined in this study. In patients
suspected of type 2A von Willebrand syndrome
or disease, this test is performed even if it is less
sensitive compared with gel electrophoresis and
Platelet Function Analyzer-100 (Siemens, Marburg,
Germany). Moreover, multimer analysis is not stan-
dardized, and there are substantial differences
between various tests, which might hamper the
interpretation of the results.
It is generally acknowledged that early diagnosis
and appropriate treatment of HS, which frequently
manifests as obscure or recurrent GI bleeding, are
essential, although clinically relevant bleeding in
AS patients appears to be less common in clinical
practice than would be expected based on a high
incidence of type 2A von Willebrand syndrome in
this disease. Growing evidence indicates that AVR
and TAVR offer long-term resolution of bleeding in
most patients with severe AS. The study by Span-
genberg et al. (12) supports the view that TAVR is an
effective and safe option in symptomatic AS patients
with a history of severe GI bleeding or refractory
anemia of unknown origin. It remains to be estab-
lished which laboratory tests should be performed to
optimally manage AS patients who are not suitable
for AVR or refuse surgery.
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